Silo Pharma, Inc. (OTCQB: SILO), a development-stage psychedelic biopharmaceutical firm, announced that the company’s patented topically applied ketamine formulation has completed a successful study in animal trials with favorable results demonstrated.
Silo Pharma Topical Ketamine Trial Results
Silo’s topical ketamine preparation reduced mechanical allodynia and hyperalgesia at both the pre-and post-dosing time points, and mechanical hyperalgesia was reduced on day seven at the pre-dose time point according to a company release.
Based on these findings, the dosing of Ketamine with a patented delivery system supplied in partnership with Silo Pharma’s partner, Zylo Therapeutics, was deemed to be effective in reducing neuropathic nerve pain in a laboratory study.
Eric Weisblum, CEO of Silo Pharma was optimistic about the results stating, “These positive results of our study show that Silo is able to successfully formulate and deliver ketamine topically at reduced dosage to achieve its endpoint of pain reduction.”
The Silo Pharm CEO continued expanding on the safety and toxicology, “Additionally, I am delighted to report that Day seven and Day nine scores averaged zero (no erythema or swelling present) for all groups, which bodes extremely well for our planned toxicology study.”
Mr. Weisblum also stated that he believes the data is extremely promising for patients suffering from Fibromyalgia and Rheumatoid Arthritis.
About Hyperalgesia & Mechanical Allodynia
Hyperalgesia is a heightened sensitivity to pain and an intense reaction to it. When nerve fibers or neurotransmitter levels are altered in the sensory nerves that transmit sensation, hyperalgesia can occur.
Mechanical allodynia, or “other pain,” is a distressing sensation caused by minimally painful stimuli such as the light touch. Allodynia lacks any apparent evolutionary purpose, unlike inflammatory hyperalgesia, which serves a defensive function.
About Silo Pharma
Silo Pharma. Inc. is a biopharmaceutical firm engaged in the development of psychedelics combined with traditional therapies for people with serious psychological conditions such as post-traumatic stress disorder (PTSD), Parkinson’s disease, and other rare neurological diseases.
The company’s pipeline includes the following developments:
- SPC-14 – Targeting Alzheimer’s
- SPC-15 – Targeted prophylactic treatment—Stress-induced affective disorders
- SPC-26 – Time-Released Psilocybin, Ketamine
- SPU-16 – CNS Homing Peptide targeting Multiple Sclerosis
- SPU-21 – Arthritogenic Joint Homing Peptides Utilizing Psilocybin